anthrax
Fighting Parasitic Infections: Promise in Cyclic Peptides
Posted on by Dr. Francis Collins
Caption: Cyclic peptide (middle) binds to iPGM (blue).
Credit: National Center for Advancing Translational Sciences, NIH
When you think of the causes of infectious diseases, what first comes to mind are probably viruses and bacteria. But parasites are another important source of devastating infection, especially in the developing world. Now, NIH researchers and their collaborators have discovered a new kind of treatment that holds promise for fighting parasitic roundworms. A bonus of this result is that this same treatment might work also for certain deadly kinds of bacteria.
The researchers identified the potential new therapeutic after testing more than a trillion small protein fragments, called cyclic peptides, to find one that could disable a vital enzyme in the disease-causing organisms, but leave similar enzymes in humans unscathed. Not only does this discovery raise hope for better treatments for many parasitic and bacterial diseases, it highlights the value of screening peptides in the search for ways to treat conditions that do not respond well—or have stopped responding—to more traditional chemical drug compounds.
Promoting Health, Science, and Public Trust through Laboratory Safety
Posted on by Drs. Francis Collins, Sally Rockey, Lawrence Tabak, and Amy Patterson
As you may know from recent news reports, there have been lapses in safety practices at federal laboratories involving potentially lethal microbes such as avian flu (H5N1) and anthrax, including an incident involving discovery of 60-year old smallpox vials in an FDA laboratory building located on the National Institutes of Health (NIH) campus in Bethesda, MD. Such lapses, which undermine public confidence in biomedical research and could put people’s health at risk, remind us of the need for constant attention to biosafety standards.
Scientists can never become complacent in routine safety practices—one mistake could have serious repercussions. Consequently, we at NIH are taking remedial action and precautionary steps to improve our lab safety protocols and procedures, minimize the risk of recurrence, and increase timely reporting of potential problems.
